Adjusted estimates for time-to-event endpoints
نویسندگان
چکیده
منابع مشابه
Adjusted estimates for time-to-event endpoints.
In the analysis of retrospective data or when interpreting results from a single-arm phase II clinical trial relative to historical data, it is often of interest to show plots summarizing time-to-event outcomes comparing treatment groups. If the groups being compared are imbalanced with respect to factors known to influence outcome, these plots can be misleading and seemingly incompatible with ...
متن کاملBayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
A two-stage model for evaluating both trial-level and patient-level surrogacy of correlated time-to-event endpoints has been introduced, using patient-level data when multiple clinical trials are available. However, the associated maximum likelihood approach often suffers from numerical problems when different baseline hazards among trials and imperfect estimation of treatment effects are assum...
متن کاملAdjusted Power Estimates
Critical values and powers of competing tests are often evaluated through Monte Carlo simulations. Since the true levels of those tests are often very diierent, comparisons of the power estimates are not valid. We suggest that Monte Carlo estimates of critical values be used to create adjusted power estimates which are then comparable. The main contribution is to analyze the variability of the ...
متن کاملBiomarker-driven population enrichment for adaptive oncology trials with time to event endpoints.
The development of molecularly targeted therapies for certain types of cancers has led to the consideration of population enrichment designs that explicitly factor in the possibility that the experimental compound might differentially benefit different biomarker subgroups. In such designs, enrollment would initially be open to a broad patient population with the option to restrict future enroll...
متن کاملSemiparametric regression analysis for time-to-event marked endpoints in cancer studies.
In cancer studies the disease natural history process is often observed only at a fixed, random point of diagnosis (a survival time), leading to a current status observation (Sun (2006). The statistical analysis of interval-censored failure time data. Berlin: Springer.) representing a surrogate (a mark) (Jacobsen (2006). Point process theory and applications: marked point and piecewise determin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Lifetime Data Analysis
سال: 2008
ISSN: 1380-7870,1572-9249
DOI: 10.1007/s10985-008-9098-9